Ontario Teachers Pension Plan Board cut its position in United Therapeutics Co. (NASDAQ:UTHR) by 70.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,800 shares of the biotechnology company’s stock after selling 27,700 shares during the period. Ontario Teachers Pension Plan Board’s holdings in United Therapeutics were worth $1,335,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in UTHR. HL Financial Services LLC increased its holdings in shares of United Therapeutics by 40.2% in the first quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 589 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of United Therapeutics by 0.7% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 125,363 shares of the biotechnology company’s stock valued at $14,086,000 after purchasing an additional 933 shares during the period. Westpac Banking Corp increased its holdings in shares of United Therapeutics by 455.2% in the first quarter. Westpac Banking Corp now owns 13,975 shares of the biotechnology company’s stock valued at $1,570,000 after purchasing an additional 11,458 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in shares of United Therapeutics by 7.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 75,834 shares of the biotechnology company’s stock valued at $8,454,000 after purchasing an additional 5,509 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of United Therapeutics in the first quarter valued at about $266,000. 95.86% of the stock is currently owned by institutional investors and hedge funds.
United Therapeutics stock opened at $119.24 on Thursday. The stock has a market cap of $5.36 billion, a P/E ratio of 6.88, a P/E/G ratio of 27.76 and a beta of 1.24. United Therapeutics Co. has a 52 week low of $100.57 and a 52 week high of $152.55. The company has a current ratio of 4.64, a quick ratio of 4.35 and a debt-to-equity ratio of 0.10.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, topping the consensus estimate of $2.57 by $1.41. The firm had revenue of $444.50 million for the quarter, compared to analyst estimates of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. United Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the company earned $4.37 earnings per share. research analysts anticipate that United Therapeutics Co. will post 14.77 earnings per share for the current fiscal year.
In other United Therapeutics news, Director Judy D. Olian sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $112.38, for a total value of $67,428.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,080 shares of company stock worth $852,966. 8.20% of the stock is owned by corporate insiders.
UTHR has been the topic of a number of research reports. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a report on Thursday, August 16th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 11th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 target price on the stock in a report on Saturday, July 7th. Wedbush set a $253.00 target price on United Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, HC Wainwright set a $95.00 target price on United Therapeutics and gave the stock a “hold” rating in a report on Monday, August 13th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. United Therapeutics has an average rating of “Hold” and a consensus price target of $138.86.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.